09.07.20: Not intended for U.S. and UK Media
Bayer's finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetesFinerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care / Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events / Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized / Finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes / Bayer will discuss the data with health authorities regarding the submission of marketing authorization applicationmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Marketing | Pharmaceuticals | Study | Urology & Nephrology